VivoSeq
Cardiovascular

Major Cardiovascular Event

0

Pipeline Programs↗

2

Active Trials↗

4

Companies Involved↗

Major Cardiovascular Event is an early-stage landscape with 0 programs across 4 companies. The most active players are Pfizer, Novartis, Sanofi.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

50/100

Attrition Rate

33/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

0 programs

PreclinicalNovartis logo

Novartis

0 programs

PreclinicalSanofi logo

Sanofi

0 programs

PreclinicalAmgen logo

Amgen

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

6

clinical trials

Completed2 · 33%
Terminated2 · 33%
Active, not recruiting1 · 17%
Recruiting1 · 17%

Clinical Trials

Trial Activity

6 trials

A Real-world, Prospective, Observational Study Assessing the Effectiveness of Repatha® Used in Combination With Standard of Care Compared With Standard of Care Alone on Major Cardiovascular Events in Chinese Patients With Established Atherosclerotic Cardiovascular Disease
Recruiting·Amgen logoAmgen·N/A·NCT06295679·7,000 enrolled
Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD
Active, not recruiting·Novartis logoNovartis·Phase 3·NCT04023552·8,323 enrolled
Incidence of Major Cardiovascular Events in Diabetic Patients With ACS Undergoing Coronary Angioplasty and Treated With Clopidogrel 150 mg Versus 75 mg
Completed·LLaboratoires Teriak·Phase 4·NCT03329261·167 enrolled
An Open-label, Non-comparative Study to Document the Tolerability to Ramipril in Patients With at Least One High Risk for Developing a Major Cardiovascular Event
Completed·Sanofi logoSanofi·Phase 4·NCT03099213·179 enrolled
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Terminated·Pfizer logoPfizer·Phase 3·NCT01975376·16,784 enrolled
The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Terminated·Pfizer logoPfizer·Phase 3·NCT01975389·10,564 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)